TRACON Pharmaceuticals, Inc. (TCON)

Market Cap	37.09M
Revenue (ttm)	n/a
Net Income (ttm)	-29.85M
Shares Out	22.21M
EPS (ttm)	-1.48
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	82,458
Open	1.72
Previous Close	1.73
Day's Range	1.67 - 1.75
52-Week Range	1.10 - 3.00
Beta	1.34
Analysts	Buy
Price Target	9.52 (+470.06%)
Earnings Date	Mar 21, 2023

About TCON

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of soft tissue sarcoma; and YH001, an investigational humanized CTLA-4 IgG1 monoclonal antibody for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelio...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Jan 30, 2015
• Employees: 19
• Stock Exchange: NASDAQ
• Ticker Symbol: TCON

Analyst Forecast

According to 11 analysts, the average rating for TCON stock is "Buy." The 12-month stock price forecast is $9.52, which is an increase of 470.06% from the latest price.

Price Target

$9.52

(470.06% upside)

Analyst Consensus: Buy